Skip to main content
Explore URMC

menu

Skin Cancer: Study of REGN2810 in Patients With Advanced Cutaneous Squamous Cell Carcinoma

Research Question:
What are the good or bad effects of REGN2810 in patients with advanced cutaneous squamous cell carcinoma? These effects could be good (for example, shrinking of tumors) or bad (called side effects).

Basic Study Information

Purpose:
REGN2810 is a type of drug called a monoclonal antibody. Antibodies are proteins that are naturally found in your blood stream that fight infections. A monoclonal antibody is a special kind of antibody that is created in a laboratory. It is a medication that binds to specific proteins in the body that may be involved in your cancer. This study is being done to test if REGN2810 can reduce the size of your tumor by helping the immune system destroy the tumor. The study is also being done to test the safety of REGN2810 in CSCC patients.

Location: cancer center
Study Web URL:  https://clinicaltrials.gov/ct2/show/NCT02760498?term=R2810-ONC-1540&rank=1
Study Reference #: IHAN-16064

Lead Researcher (Principal Investigator)

Lead Researcher: Sherrif Ibrahim

Study Contact Information

Study Coordinator: Amy Jasek
Phone: (585) 273-1912
Email: Amy_Jasek@urmc.rochester.edu

Additional Study Details

Learn More About These Conditions

More information about Carcinoma, Squamous Cell

Return to Search